http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112675176-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-14 |
| filingDate | 2020-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112675176-B |
| titleOfInvention | Application of ITM-1A8 in preparation of drugs for preventing and/or treating tumors |
| abstract | The invention discloses a new application of ITM-1A 8. The new application comprises the following steps: 1) preparing a product that inhibits the interaction of KLHL22 with DEPDC 5; 2) preparing a eukaryotic tumor cell proliferation inhibitor; 3) preparing a product for preventing and/or treating tumors. The ITM-1A8 was screened by using the KLHL22-DEPDC5 interaction model, and the intensity of the interaction between KLHL22 and DEP was significantly lower than that of the control group when added to the cells of ITM-1A 8. Indicating that the compound has the function of inhibiting the KLHL22-DEP interaction. The anti-cancer effect of the compound ITM-1A8 is verified by typical triple negative breast cancer cells MDA-MB-231, and the result shows that the number of the cells added into a drug group is far lower than that of a control group, which indicates that the compound has the effect of inhibiting the growth of triple negative breast cancer cells. |
| priorityDate | 2020-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 351.